Reviewer's report

Title: Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a novel glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease

Version: 3 Date: 18 June 2014

Reviewer: Edward Kerwin

Reviewer's report:

I would approve this manuscript for publication. The changes look good.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have served on advisory boards, speaker panels, or received travel reimbursement for Amphastar, Astra Zeneca, Forest, Ironwood, Merck, Mylan, Novartis, Pearl, Pfizer, Sanofi Aventis, Sunovion, Targacept, Teva and Theravance. He has conducted multicenter clinical research trials for approximately seventy pharmaceutical companies.